Paper - WANFANG MED ONLINE

You Position: Home > Paper

基质金属蛋白酶与其抑制剂在消化道肿瘤中的研究进展

( views:227, downloads:17 )

Author:: No author available

Journal Title:: WORLD CHINESE JOURNAL OF DIGESTOLOGY

Issue:: 11

DOI:: 10.3969/j.issn.1009-3079.2004.11.037

Key Word:: No keyword available

Abstract： MMP和TIMP之间的相互平衡可以保证机体在生理状态下的细胞迁移和细胞外基质重构.MMP和TIMP之间平衡失调在细胞外基质降解这一过程中起决定性作用,为肿瘤早期浸润的标志,在肿瘤细胞侵袭和转移等病理过程中也发生作用.基质金属蛋白酶MMP因其强烈恶性组织特性并具有独特的分解各种细胞外基质能力,被确定是有希望的癌症治疗靶位.由于认识到MMP在肿瘤侵袭及转移中起着重要的作用,因此对MMP的抑制剂的研究也倍受重视,这类抑制剂有可能成为广谱抗肿瘤治疗剂,通过MMPs,TIMPs表达量的检测可以协助临床恶性肿瘤的早期诊断,判断良性肿瘤,特别是交界性肿瘤的转归,从而指导临床预防抗肿瘤治疗.通过研究MMP-TIMP之间及肿瘤与宿主细胞间的相互作用,为临床恶性肿瘤的诊断,预后判断及治疗提供理论及试验依据,对临床实践具有一定的指导意义.

Reference

[1]王璐,张丽红,李玉林,等.基质金属蛋白酶-9及其mRNA在胃癌中的表达与血管新生的关系[J].2003,(9).
[2]孙晋民,郑华川,杨雪飞,等.基质金属蛋白酶-7表达与胃癌临床病理生物学行为的关系[J].2003,(9).
[3]陶厚权,邹寿椿,王瑞年,等.血管生成与胃癌发生之间关系的实验研究[J].2003,(1).
[4]Sheng ZHANG,Li Li,Jian-Yin Lin,etc.Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma[J].2003,(5).
[5]李莉,张声,林华,等.基质金属蛋白酶和组织金属蛋白酶抑制剂表达失衡与胃癌浸润转移的关系[J].2002,(3).
[6]郭文忠,冉宇靓,王贵齐,等.VEGF和MMP-9在食管癌中的表达及低氧调节[J].2002,(1).
[7]李新华,张桂英,罗非君,等.胃癌细胞系幽门螺杆菌感染对金属蛋白酶表达的影响[J].2003,(5).
[8]ol.com,Siegel SE,Bodey B Jr,etc.Prognostic significance of matrix metalloproteinase expression in colorectal carcinomas.[J].2000,14(5).
[9]J, Westermarck,V M, K?h?ri.Regulation of matrix metalloproteinase expression in tumor invasion.[J].1999,13.
[10]Makino T,Watanabe G,Imamura M,etc.Expression of vascular endothelial growth factor, matrix metalloproteinase-9 and E-cadherin in the process of lymph node metastasis in oesophageal cancer.[J].1999,80(9).
[11]Zucker S,Vacirca J.Role of matrix metalloproteinases (MMPs) in colorectal cancer.[J].2004,23(1).
[12]Michael M,Chamberlain D,Babic B,etc.Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer.[J].1999,17(6).
[13]Z S, Zeng,A M, Cohen,J G, Guillem.Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis.[J].1999,20.
[14]Leco KJ,Muzik H,Brasher PM,etc.Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas.[J].1999,79(11).
[15]Matthew G, Tutton,Mark L, George,Suzanne A, Eccles,etc.Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients.[J].2003,107.
[16]Samantaray S,Sharma R,Chattopadhyaya TK,etc.Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma.[J].2004,130(1).
[17]Morris TM,Collins HM,Watson SA.Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase.[J].2001,84(12).
[18]Parsons SL,Watson SA,Collins HM,etc.Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy[J].1998.
[19]Heike Allgayer,Rudolf Babic,Klaus Uwe Grützner,etc.Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns[J].1998,16(1).